Clinical Trials

Below you will find an overview of some important publications with authors from the ISCC. The overview is limited to publications in which ISCC-authors are named first or last. Further publications will be added soon.

1. An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile
   Wu X, Schmidt-Wolf IGH. An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile. Front Immunol. 2022 May 23;13:913123. doi: 10.3389/fimmu.2022.913123. PMID: 35677035; PMCID: PMC9170073.
2. Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials
   Zhang Y, Sharma A, Weiher H, Schmid M, Kristiansen G, Schmidt-Wolf IGH. Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials. Cancers (Basel). 2021 Nov 29;13(23):6007. doi: 10.3390/cancers13236007. PMID: 34885117; PMCID: PMC8656601.
3. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
   Sharma A, Schmidt-Wolf IGH. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J Exp Clin Cancer Res. 2021 Dec 9;40(1):388. doi: 10.1186/s13046-021-02184-2. PMID: 34886895; PMCID: PMC8662881.
4. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
   Hu C, Liu M, Li Y, Zhao Y, Sharma A, Liu H, Schmidt-Wolf IGH. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer. Front Immunol. 2023 Jun 29;14:1213716. doi: 10.3389/fimmu.2023.1213716. PMID: 37457699; PMCID: PMC10346844.
5. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside
   Li Y, Sharma A, Maciaczyk J, Schmidt-Wolf IGH. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside. Int J Mol Sci. 2022 Jan 24;23(3):1311. doi: 10.3390/ijms23031311. PMID: 35163235; PMCID: PMC8835986.